Citations

Clear

21 citation(s) found for "Smith, Eric".

Key points from the 2026 multisocietal acute pulmonary embolism guidelines: Perspectives of some SVM members on the writing committee
Porres‐Aguilar, Mateo , Piazza, Gregory, Barnes, Geoffrey D. , Mukherjee, Debabrata , Secemsky, Eric A. , Creager, Mark A. , Porres-Aguilar, Mateo , Creager, Mark A , Secemsky, Eric A , Mukherjee, Debabrata , Piazza, Gregory

Mayo Clinic

Vascular Medicine | August 13, 2026 | Volume: 31 | Issue: 4 | Pages: 617-620

10.1177/1358863x261469140 | PMID 42591043 Get It

The vascular contribution to dementia: World Stroke Organization scientific statement
Biessels, Geert Jan , Debette, Stephanie, Elahi, Fanny M, Geranmayeh, Fatemeh, Hansra, Gurpreet , Hughes, Timothy M, Ihara, Masafumi, Isaacs, Jeremy, Jokinen, Hanna, Nott, Alexi, Pendlebury, Sarah, Peters, Ruth, Schneider, Julie, Smith, Colin, Vemuri, Prashanthi, Webb, Alastair J.S. , Wilcock, Donna M, Hainsworth, Atticus H. , Hansra, Gurpreet K , Smith, Eric Edward , Wardlaw, Joanna Marguerite , Webb, Alastair Js , Hainsworth, Atticus H , Biessels, Geert Jan , Debette, Stéphanie , Elahi, Fanny M. , Geranmayeh, Fatemeh , Hughes, Timothy M. , Ihara, Masafumi , Isaacs, Jeremy D. , Jokinen, Hanna , Nott, Alexi , Pendlebury, Sarah Tamsin , Peters, Ruth , Schneider, Julie A. , Vemuri, Prashanthi , Wilcock, Donna M.

Mayo Clinic

International Journal of Stroke | July 15, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/17474930261470506 | PMID 42454751 Get It

Background: Alzheimer’s disease (AD) and cerebrovascular pathology are the two most common causes of dementia, frequently co-occurring in older people. Community-based neuropathology studies indicate that vascular disease accounts for approximately one-third of the population-attributable risk of dementia, controlling for other pathologies (including AD). The proportion with vascular disease as co-pathology is likely to be higher (50–70%). The most common vascular substrate is cerebral small vessel disease, which includes small artery fibrosis (arteriolosclerosis), vascular amyloid deposits (cerebral amyloid angiopathy), and monogenic forms of small vessel disease, the commonest being Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL). Post-stroke cognitive impairment following both ischemic stroke and intracerebral hemorrhage also contributes. Aims and Methods: In this World Stroke Organization (WSO) scientific statement, we assembled a multi-disciplinary international group of experts to review the vascular contribution to dementia, encompassing both vascular and neurodegenerative dementia. This statement has been reviewed and approved by the WSO executive. Results: We summarize the epidemiology, neuropathology, cognitive profile, clinical impact and management of vascular disease in dementia and discuss the recent VasCog-2-WSO diagnostic criteria. We consider the substantial overlap with clinical stroke and with AD dementia. We catalog transcriptomic and proteomic studies that have revealed novel candidate molecules ( COL4A1/4A2, HTRA1, TRIM47, FOXF2 ) as possible treatment targets. We appraise imaging-based biomarkers relevant to vascular disease and potential biochemical markers (vascular endothelial growth factor-A, placental growth factor, interleukin-6, matrix metalloproteinase-9, cathepsin-B). We highlight the potential for vascular interventions to treat not only vascular dementia but also the vascular component of neurodegenerative dementia. We review recent clinical trials targeting multiple pathways, including nitric oxide signaling, high blood pressure, the GABAergic system, angiogenic activity, microglial inhibition, PDE3 and PDE5 inhibition, as well as dietary supplementation with omega-3 fatty acids, s-equol and vitamin E. Finally, we consider upcoming opportunities and challenges relevant to vascular disease in dementia. Conclusion: The vascular contribution to dementia is i) substantial, ii) increasingly understood at molecular and mechanistic levels, iii) a source of potential treatment opportunities. Data Access Statement: no original data are presented in this document.
Plasma cell identity escape drives resistance to anti-BCMA T-cell–redirecting therapy in multiple myeloma
Freeman, Ciara L. , Garcés, Juan-José, Lee, Holly , Papadimitriou, Marios , Silva, Ariosto Siqueira , Füller, Etta Rozen , Agius, Phaedra , Hansen, Doris K., Zhao, Xiaohong , Meads, Mark B. , Teer, Jamie K. , Hagner, Patrick R. , Alsina, Melissa , Ramasubramanian, Anusuya , Smith, Eric L. , Mailankody, Sham , Chesi, Marta, Hamadeh, Issam S. , Shain, Kenneth H. , Ilundain, Marta Larrayoz , Durante, Michael , Sharik, Meaghen E. , Du, Megan T. , Hagner, Patrick, Bergsagel, P. Leif , Landgren, C Ola , Maura, Francesco , Maclachlan, Kylee , Larráyoz, Marta , Ziccheddu, Bachisio , Meermeier, Erin W. , Garcés, Juan‐José , Durante, Michael , Firestone, Ross , Menges, Meghan A. , Reid, Kayla M. , Diamond, Benjamin , Sudalagunta, Praneeth Reddy , Leblay, Noémie , Ahn, Sungwoo , Fuller, Ethan, Briercheck, Edward L. , Hansen, Doris K. , Song, Xiaofei , Jelı́nek, Tomáš , Baz, Rachid , Smith, Eric, Giralt, Sergio , Bergsagel, P. Leif , Neri, Paola , Chesi, Marta , Martinez‐Climent, José A. , Locke, Frederick L. , Bahlis, Nizar Jacques , Landgren, Ola , Usmani, Saad Z.

Mayo Clinic

No container title available | December 15, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2025.12.08.692978 | PMID 41415462 Get It

ABSTRACT Chimeric antigen receptor T-cell (CART) and T-cell engager (TCE) therapies targeting B-cell maturation antigen (BCMA) are transforming the treatment landscape for relapsed multiple myeloma (MM). However, despite impressive initial response rates, most patients eventually relapse. To investigate this unmet medical need, we applied whole-genome sequencing (WGS) to MM cells from cohorts of 102 relapsed patients treated with anti-BCMA CART and TCE therapies. Several genomic alterations were associated with clinical outcomes, particularly primary refractoriness, including high genomic complexity and mutations in genes regulating plasma cell identity, which predicted resistance to therapy. Single-cell RNA sequencing further revealed that MM cells from refractory patients exhibited high proliferation signatures and reduced expression of TNFRSF17 (encoding BCMA), while were less enriched for plasma cell–associated transcriptional programs, a phenomenon we term “plasma cell identity escape.” This profile was strongly associated with immune dysregulation of CD8 T cells including increased activation and exhaustion. This evolution of MM toward a more proliferative and lineage-divergent state, refractory to the anti-BCMA T-cell redirecting therapies, was functionally validated in preclinical MM mouse models. Collectively, our results comprehensively define the cellular and molecular mechanisms underlying primary resistance to anti-BCMA therapies.
Intravenously administered LV-169 delivers a functional BCMA-CAR transgene to niche-resident T cells and leads to elimination of disseminated myeloma in MHC-deficient NSG mice
Nenavath, Gopal Naik, Gazi, Md Yeashin, Hawkes, Aaron, Gwilt, Collin, Chin, Chia-Hsuan , Kinney, Christian, Salimi, Hamid , Suwanmanee, Thipparat, Phung, Darren, Briercheck, Edward L. , Smith, Eric L. , Lin, Yi , Peng, Kah-Whye , Packiriswamy, Nandakumar , Carey, Timothy S. , Phung, Darren, Krotova, Karina Y. , Vandergaast, Rianna , Venugopal, Kartika , Smith, Eric

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5896-5896

10.1182/blood-2025-5896 Get It

Abstract Chimeric Antigen Receptor (CAR) T cell therapy is a transformative treatment for hematologic malignancies. However, ex vivo autologous CAR T cell manufacturing presents substantial logistical and clinical challenges. Direct in vivo CAR-T cell engineering offers a new paradigm for CAR T delivery. We recently developed the CD3-targeted lentiviral vector LV-169 which can deliver a CAR transgene to resting niche-resident T cells in lymphoid tissues. LV169 is pseudotyped with a mix of chimeric and nonchimeric VSV-G proteins detargeted (blinded) from the natural LDL receptor and re-targeted to T cells through the display of a CD3-specific scFv. Here we demonstrate that LV169 can specifically deliver a functional aBCMA-CAR transgene to resting human T cells in PBMC cultures from the healthy volunteers and from multiple myeloma patients. For clinical translation, we selected an αBCMA-CAR construct comprising a fully human single heavy chain nanobody linked to 41BB and CD3z cytoplasmic signaling domains. Human T cells expressing this CAR construct have low tonic signaling and efficiently kill BCMA-positive myeloma target cells with similar or lower associated cytokine release compared to a clinically relevant benchmark BCMA-CAR. To further improve LV169 and to minimize CAR protein incorporation in the LV envelope which may lead undesirably to myeloma cell transduction, we placed the CAR transgene under a T-cell specific Lck promoter in reverse orientation relative to the 5' LTR. The transcriptional activity of the Lck promoter was comparable to that of a constitutive EF1a promoter in primary T cells and, in contrast to EF1a had minimal activity in a variety of other tested cell types including the HEK293T producer cell line and the THP-1 monocytic cell line. Western blotting confirmed the absence of CAR protein in LV particles (LVP) generated using the Lck promoter-driven reverse orientation construct. In contrast, high levels of CAR protein were detected in LVP generated using the parental EF1a promoter-driven construct. The LV-incorporated CAR protein mediated off-target gene delivery to BCMA-positive myeloma cells. The therapeutic efficacy of intravenously administered LV169 LV particles carrying BCMA-CAR constructs was tested in the OPM-2 human multiple myeloma xenograft model. NSG mice with knockout of MHC-I and MHC-II, and with advanced disseminated OPM-2-Luc tumors were engrafted with human PBMC one week prior to intravenous LV169-BCMA-CAR administration. Mice were treated with single intravenous injection of LV169 at different doses 3 weeks after tumor engraftment. OPM-2-Luc tumor burden was monitored by regular luciferase imaging. All treated mice cleared their tumors within 28-days following LV administration and the rate of clearance was correlated to the LV particle dose. Even at the 4e8 dose level (by p24) tumors were completely cleared. Eighty four days post-treatment the treated mice remained tumor-free and resisted re-challenge with OPM-2 tumor cells. Circulating CAR-T cells, monitored by flow cytometry, became detectable by 14 dpi and peaked between 21-35 dpi. Following tumor clearance, the number of circulating CAR-T cells declined dramatically. The treatment was well tolerated and analysis of cytokines associated with CAR-T cell cytotoxicity confirmed the absence of a severe cytokine storm. IFNγ was the only cytokine which was elevated during the expansion period of CAR-T cells, while IL-2, IL-6, TNFα and GM-CSF were barely detectable. In summary the characteristics of our new developed LV169-based platform make it suitable for further clinical translation which is underway.
Correction: Endoluminal radiofrequency ablation with stenting versus stenting alone in patients with malignant biliary obstruction: a meta-analysis of randomized trials
Ramai, Daryl , Maida, Marcello , Wang, Yichen , Chandan, Saurabh , Huang, Yuting , Tokmak, Salih , DuBroff, Jason, Ko, Christopher , Morris, John D., Khashab, Mouen A., Wang, Yichen , Chandan, Saurabh , Huang, Yuting , Tokmak, Salih , Marasco, Giovanni , Crinò, Stefano Francesco , Facciorusso, Antonio , Mangiavillano, Benedetto , Smith, Eric R. , Spadaccini, Marco , Previtera, Melissa J. , Bhandari, Peter , Marasco, Giovanni , Crinò, Stefano Francesco , Facciorusso, Antonio , Khashab, Mouen A.

Mayo Clinic

Endoscopy | July 28, 2025 | Volume: 57 | Issue: 09 | Pages: C11-C11

10.1055/a-2664-6391 | PMID 40720957 Get It

Implementing the 2024 ACC/AHA Multisocietal PAD guidelines into clinical practice: Key changes from the 2016 guidelines
Cohoon, Kevin P. , Henkin, Stanislav , Tomihama, Roger T. , Thomas, Sneha , Porres‐Aguilar, Mateo , Brunton, Nichole , Hornacek, Deborah , Secemsky, Eric A. , Brunton, Nichole E , Porres-Aguilar, Mateo , Tomihama, Roger , Henkin, Stanislav , Secemsky, Eric A

Mayo Clinic

Vascular Medicine | December 23, 2024 | Volume: 30 | Issue: 1 | Pages: 110-113

10.1177/1358863x241306354 | PMID 39713878 Get It

Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)
Chertkow, Howard , Rockwood, Kenneth, Bartha, Robert , Beaudoin, Camille, Bélanger, Nathalie , Bellec, Pierre , Belleville, Sylvie, Bergman, Howard , Best, Sarah, Bherer, Louis , Borrie, Michael, Camicioli, Richard , Chan, Senny , Crowshoe, Lynden , Cynader, Max S., Das, Samir , Dixon, Roger A., Ducharme, Simon , Fahnestock, Margaret , Feldman, Howard , Ferland, Guylaine , Fogarty, Jennifer, Gauthier, Serge, Greenwood, Carol E., Henri-Bellemare, Charlie, Herrmann, Nathan, Itzhak, Inbal, Jacklin, Kristen , Mackenzie, Ian R. , Masellis, Mario, Maxwell, Colleen J. , McLaurin, JoAnne, Mohades, Zia, Montero‐Odasso, Manuel , Morgan, Debra, Nygaard, Haakon B. , O’Connell, Megan E. , Petersen, Ron, Pilon, Randi, Rajah, Maria Natasha, Rapoport, Mark , Roach, Pamela, Robillard, Julie M. , Rylett, R. Jane , Sadavoy, Joel , Seitz, Dallas , Walker, Jennifer , Whitehead, Victor, Wittich, Walter , Feldman, Howard H , Phillips, Natalie A. , Rockwood, Kenneth J. , Anderson, Nicole D. , Andrew, Melissa Kathryn , Bélanger, Nathalie, Belleville, Sylvie , Bethell, Jennifer , Black, Sandra E. , Carrier, Julie C , Cashman, Neil R. , Cuello, A. Claudio , Dang‐Vu, Thien Thanh , Einstein, Gillian , Evans, Alan Charles , Finger, Elizabeth C. , Fisk, John D. , Fon, Edward A , Gan‐Or, Ziv , Hogan, David B. , Hsiung, Ging‐Yuek Robin , Lanctôt, Krista L. , Lim, Andrew S. P. , McAiney, Carrie A. , McGilton, Katherine S. , McLaurin, JoAnne , Mihailidis, Alex , Morgan, Debra, Naglie, Gary , Rajah, Maria Natasha , Rogaeva, Ekaterina A. , Rosa-Neto, Pedro , George‐Hyslop, Peter St , Smith, Eric Edward , Stefanovic, Bojana , Vedel, Isabelle , Wellington, Cheryl L.

Mayo Clinic

Journal of Alzheimer’s Disease | December 5, 2024 | Volume: 102 | Issue: 3 | Pages: 535-561

10.1177/13872877241290990 | PMID 39636028 Get It

The Canadian Consortium on Neurodegeneration in Aging (CCNA) was created by the Canadian federal government through its health research funding agency, the Canadian Institutes for Health Research (CIHR), in 2014, as a response to the G7 initiative to fight dementia. Two five-year funding cycles (2014–2019; 2019–2024) have occurred following peer review, and a third cycle (Phase 3) has just begun. A unique construct was mandated, consisting of 20 national teams in Phase I and 19 teams in Phase II (with research topics spanning from basic to clinical science to health resource systems) along with cross-cutting programs to support them. Responding to the needs of researchers within the CCNA teams, a unique sample of 1173 deeply phenotyped patients with various forms of dementia was accrued and studied over eight years (COMPASS-ND). In the second phase of funding (2019–2024), a national dementia prevention program (CAN-THUMBS UP) was set up. In a short time, this prevention program became a member of the World Wide FINGERS prevention consortium. In this article, the challenges, successes, and impacts of CCNA in Canada and internationally are discussed. Short-term deliverables have occurred, along with considerable promise of impacts in the longer term. The creation of synergy, networking, capacity building, engagement of people with lived experience, and economies of scale have contributed to the considerable success of CCNA by all measures. CCNA is evidence that an organized “centrally-organized” approach to dementia research can catalyze important progress nationally and yield significant and measurable results.
Steering the multidisciplinary landscape of vascular medicine: Collaboration as the key to success for aspiring vascular medicine specialists
Cohoon, Kevin P. , Porres‐Aguilar, Mateo , Tomihama, Roger T. , Thomas, Sneha , Rogers, Everett M., Brunton, Nichole , Henkin, Stanislav , Hornacek, Deborah , Secemsky, Eric A. , Buckley, Anthony , Brunton, Nichole E , Henkin, Stanislav , Secemsky, Eric A , Porres-Aguilar, Mateo , Tomihama, Roger

Mayo Clinic

Vascular Medicine | August 13, 2024 | Volume: 29 | Issue: 4 | Pages: 462-466

10.1177/1358863x241262723 | PMID 39135266 Get It

Endoluminal radiofrequency ablation with stenting versus stenting alone in patients with malignant biliary obstruction: a meta-analysis of randomized trials
Ramai, Daryl , Maida, Marcello , Smith, Eric , Wang, Yichen , Chandan, Saurabh , Huang, Yuting , Tokmak, Salih , DuBroff, Jason, Ko, Christopher , Morris, John D., Marasco, Giovanni , Crinò, Stefano Francesco , Khashab, Mouen A., Chandan, Saurabh , Huang, Yuting , Tokmak, Salih , Marasco, Giovanni , Crinò, Stefano Francesco , Facciorusso, Antonio , Mangiavillano, Benedetto , Wang, Yichen , Spadaccini, Marco , Previtera, Melissa J. , Bhandari, Peter , Facciorusso, Antonio , Khashab, Mouen A.

Mayo Clinic

Endoscopy | August 2, 2024 | Volume: 57 | Issue: 03 | Pages: 272-281

10.1055/a-2378-9533 | PMID 39094769 Get It

AbstractEndoluminal radiofrequency ablation (RFA) is a palliative treatment for patients suffering from malignant biliary obstruction (MBO). We aimed to conduct a meta-analysis to evaluate the impact of RFA on stent patency, patient survival, and adverse events.Major databases were searched through December 2023 for patients who had undergone stenting with or without RFA for extrahepatic MBO. A random-effects model was used for analysis, with results expressed as relative risk ratios (RRs) with 95%CIs.Nine RCTs involving 750 subjects with MBO (374 RFA plus stent vs. 376 stent only) were included. Meta-analysis revealed similar risks of stent patency at 3 months (RR 1.01, 95%CI 0.92–1.11; I 2 = 4%) for RFA plus stenting vs. stent only. Meta-analysis showed improved survival at 6 months (RR 0.84, 95%CI 0.73–0.96; I 2 = 21%; P = 0.01) for RFA plus stenting vs. stent only. Subgroup analysis comparing plastic vs. uncovered metal stents showed that stent patency was unaffected at 3 months (RR 1.06, 95%CI 0.91–1.23; I 2 = 17%). Subgroup analysis showed that patients with cholangiocarcinoma experienced an overall survival benefit with RFA plus stenting vs. stenting alone (P < 0.001); however, stent patency remained unaffected (P = 0.08). An increased incidence of cholecystitis was noted with RFA plus stenting vs. stenting alone (5.1% [95%CI 3.1%–7.8%] vs. 0.3% [95%CI 0.01%–1.5%], respectively).Combining endoluminal RFA and stenting may improve overall survival in patients with MBO. RFA did not significantly impact stent patency.
Racial and Ethnic Disparities in Treatment of Critical Limb Ischemia: A National Perspective
Wahood, Waseem , Duval, Sue , Takahashi, Edwin A. , Secemsky, Eric A. , Misra, Sanjay , Misra, Sanjay , Takahashi, Edwin A , Secemsky, Eric A

Mayo Clinic

Journal of the American Heart Association | August 23, 2023 | Volume: 12 | Issue: 17 | Pages: No page available

10.1161/jaha.122.029074 | PMID 37609984 Get It

Background Recent guidelines have emphasized the use of medical management, early diagnosis, and a multidisciplinary team to effectively treat patients with critical limb ischemia (CLI). Previous literature briefly highlighted the current racial disparities in its intervention. Herein, we analyze the trend over a 14‐year time period to investigate whether the disparities gap in CLI management is closing. Methods and Results The National Inpatient Sample was queried between 2005 and 2018 for hospitalizations involving CLI. Nontraumatic amputations and revascularization were identified. Utilization trends of these procedures were compared between races (White, Black, Hispanic, Asian and Pacific Islander, Native American, and Other). Multivariable regression assessed differences in race regarding procedure usage. There were 6 904 562 admissions involving CLI in the 14‐year study period. The rate of admissions in White patients who received any revascularization decreased by 0.23% ( P <0.001) and decreased by 0.25% ( P =0.025) for Asian and Pacific Islander patients. Among all patients, the annual rate of admission in White patients who received any amputation increased by 0.21% ( P <0.001), increased by 0.19% ( P =0.001) for Hispanic patients, and increased by 0.19% ( P =0.012) for the Other race patients. Admissions involving Black, Hispanic, Asian and Pacific Islander, or Other race patients had higher odds of receiving any revascularization compared with White patients. All races had higher odds of receiving major amputation compared with White patients. Conclusions Our analysis highlights disparities in CLI treatment in our nationally representative sample. Non‐White patients are more likely to receive invasive treatments, including major amputations and revascularization for CLI, compared with White patients.